[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Gang Chen\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":92},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,40,62],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100637179","a-22-factorial-randomized-controlled-trial-for-ercp-100637179",false,"NCT07584902","A 2×2 Factorial Randomized Controlled Trial for ERCP","Effects of Propofol Versus Ciprofol and Sufentanil Versus Es-ketamine on Intraoperative Desaturation and Hypotension in Elderly Patients Undergoing ERCP: A 2×2 Factorial Randomized Controlled Trial","Inclusion Criteria:\n\n* Age ≥ 60 years old.\n* ASA II-III level.\n* BMI\\\u003C30kg\u002Fm2.\n* Patients who require elective therapeutic ERCP.\n* Voluntarily participate in this study and sign an informed consent form. If the subject is unable to read and sign the informed consent form due to reasons such as lack of capacity, their guardian needs to act as a proxy for the informed process and sign the informed consent form. If the subject lacks the ability to read the informed consent form (such as illiterate subjects), a witness is required to witness the informed process and sign the informed consent form.\n\nExclusion Criteria:\n\n* Previous anatomical changes in the gastrointestinal tract, delayed gastric emptying, and gastric outlet obstruction.\n* Coagulation dysfunction or tendency towards nosebleeds.\n* Combined severe heart disease (coronary heart disease, myocardial infarction, congestive heart failure, left ventricular ejection fraction\\\u003C40%, tachyarrhythmia)\n* Have a history of allergies to relevant anesthetic drugs in the past.\n* Severe pulmonary diseases (severe asthma attacks, respiratory failure, severe chronic obstructive pulmonary disease, severe interstitial lung disease, large pleural effusion, severe pulmonary arterial hypertension, etc.).\n* Existing upper respiratory tract infection (within one week).\n* Uncontrolled severe hypertension.\n* Patients with increased intracranial pressure; Cerebral hemorrhage, intracranial space occupying lesions, acute phase of traumatic brain injury.\n* Glaucoma and significant increase in intraocular pressure.\n* Untreated or inadequately treated patients with hyperthyroidism.\n* Serious liver and kidney diseases.\n* Known neurological and psychiatric disorders (Parkinson's disease, epilepsy, or schizophrenia).\n* Difficult airway: The anesthesiologist assessed the presence of difficult airway before surgery.\n* Vulnerable groups other than the elderly\u002Filliterate, including those with mental illness, cognitive impairment, critically ill patients, pregnant women, etc.","ALL","60 Years",{"count":19,"type":20},236,"ESTIMATED","INTERVENTIONAL",[23],"NA","To investigate the effects of propofol vs. cyclopropofol and sufentanil vs. esketamine on intraoperative hypoxemia and hypotension in elderly patients undergoing ERCP, as well as the interaction between these two factors.",[26,27],"Biliary and Pancreatic Diseases","Endoscopic Retrograde Cholangiopancreatography (ERCP)","NOT_YET_RECRUITING","2026-05-07",{"date":31,"type":32},"2026-05-13","ACTUAL",{"date":34,"type":20},"2026-04-27",{"date":36,"type":20},"2026-10-31",{"name":38,"class":39},"Gang Chen","OTHER",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":21,"phases":49,"briefSummary":50,"conditions":51,"keywords":4,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":61},"100594272","effect-of-deep-analgosedation-vs-endotracheal-intubation-general-anesthesia-on-on-perioperative-sedation-related-adverse-events-in-elderly-ercp-patients-100594272","NCT07017283","Effect of Deep Analgosedation vs. Endotracheal Intubation General Anesthesia on on Perioperative Sedation Related Adverse Events in Elderly ERCP Patients","Effect of Deep Analgosedation vs. Endotracheal Intubation General Anesthesia on Perioperative Respiratory Adverse Events in Elderly ERCP Patients: An Open-Label Randomized Controlled Trial","Inclusion criteria：\n\n1. Aged 60 and above;\n2. ASA physical status≤III;\n3. Patients who scheduled for elective therapeutic ERCP (ERCP complexity grading system;\n4. Willing to provide informed consent (or by legal guardian\u002Fwitness if applicable).\n\nExclusion criteria：\n\n1: Altered gastrointestinal anatomy, delayed gastric emptying, or gastric outlet obstruction； 2.Coagulopathy or epistaxis tendency; 3.Cardiac diseases (e.g., coronary artery disease, heart failure, arrhythmias); 4.Pulmonary diseases (e.g., asthma, COPD); 5.Prior hypersensitivity to anesthetic agents; 6.Active upper respiratory infection； 7.Severe liver and kidney diseases； 8.Difficult airway: Preoperative anesthesiologist assessment of difficult airway； 9.Psychiatric disorders, cognitive impairment, critical illness, or pregnancy.",{"count":48,"type":20},170,[23],"This study aims to investigate the impact of deep analgosedation versus endotracheal intubation general anesthesia on perioperative sedation related adverse events in elderly ERCP patients.",[26,27],"RECRUITING","2025-12-10",{"date":55,"type":32},"2025-12-18",{"date":57,"type":32},"2025-11-10",{"date":59,"type":20},"2026-02-28",{"name":38,"class":39},1,{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":16,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":4,"studyType":21,"phases":74,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":4},"100592845","phase-4-bcd-to-measure-the-ed95-of-remimazolam-assisted-sedation-in-arteriovenous-fistula-creation-surgery-100592845","NCT06998732","BCD to Measure the ED95 of Remimazolam-Assisted Sedation in Arteriovenous Fistula Creation Surgery","Using Biased Coin Design (BCD) to Measure the ED95 of Remimazolam-Assisted Sedation in Arteriovenous Fistula Creation Surgery","BCD","Inclusion Criteria:\n\n* 18-65 years old (including borderline values).\n* Elective surgical patients under local anaesthesia for operation of AVF\n* Voluntary participation in this study and signing of informed consent.\n* American Society of Anesthesiologists (ASA) classification \\\u003C Grade IV.\n* BMI range: 18-28kg\u002Fm2 (including borderline values).\n\nExclusion Criteria:\n\n* hypersensitivity to remimazolam or benzodiazepines.\n* patients with severe cardiac, pulmonary, neurological diseases or liver failure. -- Preoperative use of sedative drugs, anticonvulsants, etc.\n* patients who cannot cooperate with postoperative recovery or follow-up.\n* vulnerable groups, including those with mental illness, cognitive impairment, critically ill patients, pregnant women, illiterates, etc.","18 Years","65 Years",{"count":73,"type":20},40,[75],"PHASE4","This study intends to measure the ED95 of remimazolam-assisted sedation in arteriovenous fistula creation by BCD.",[78],"Uremia",[80,81,82,83],"Biased Coin Design","uremia","remimazolam","ED95","2025-05-22",{"date":86,"type":32},"2025-05-31",{"date":88,"type":20},"2025-06-01",{"date":90,"type":20},"2025-10-31",{"name":38,"class":39},""]